

**IN THE CLAIMS**

This listing of claims replaces all prior versions, and listings, in this application.

1. (original) A composition comprising a conjugate of a photosensitiser and a bacteriophage.
2. (original) A composition according to claim 1, wherein the bacteriophage is a staphylococcal bacteriophage.
3. (previously presented) A composition according to claim 1, wherein the photosensitiser is covalently linked to the bacteriophage.
4. (currently amended) A composition according to claim 1, wherein the photosensitiser is ~~chosen~~ selected from the group consisting of porphyrins, Porphyrins, phthalocyanines, chlorins, bacteriochlorins, phenothiaziniums, phenazines, acridines, texaphyrins, cyanines, anthracyclins, pheophorbides, sapphyrins, fullerene, halogenated xanthenes, perylenequinonoid pigments, gilvocarcins, terthiophenes, benzophenanthridines, psoralens and riboflavin.
5. (original) A composition according to claim 4, wherein the photosensitiser is tin (IV) chlorin e6 (SnCe6).
6. (currently amended) A composition according to claim 1, wherein the bacteriophage is ~~chosen~~ selected from the group consisting of phage 53, 75, 79, 80, 83, Φ11, Φ12, Φ13, Φ147, ΦMR11, 48, 71, Φ812, SK311, Φ131, SB-I, U16, C<sub>1</sub>, SF370.1, SP24, SFL, A1, ATCC 12202-B1, f304L, Φ304S, Φ15, Φ16, 782, P1clr100KM, P1, T1, T3, T4, T7 MS2, P1, M13, UNL-1, ACQ, UT1, tbaID3, E79, F8, pf20 B3, F116, G101, B86, T7M, ACq, UT1, BLB, PP7, ATCC 29399-B1 and B40-8.

7. (original) A composition according to claim 6, wherein the bacteriophage is phage 75 or phage  $\Phi 11$ .

8. (previously presented) A composition according to claim 1, wherein the concentration of the photosensitiser is from 0.01 to 200  $\mu\text{g/ml}$ .

9. (previously presented) A composition according to claim 1, wherein the concentration of the bacteriophage is from  $1 \times 10^5$  to  $1 \times 10^{10}$  pfu/ml.

10. (currently amended) A composition according to claim 1, which further comprises a source of  $\text{Ca}^{2+}$  ions, ~~preferably calcium chloride~~.

11. (previously presented) A composition according to claim 1, in the form of a solution in a pharmaceutically acceptable carrier.

12. (previously presented) A composition according to claim 1, wherein the composition further comprises one or more of a buffer, salt, antioxidant, preservative, gelling agent or remineralisation agent.

13. (previously presented) A method of killing bacteria, comprising

- (a) contacting an area to be treated with a composition according to claim 1, such that any bacteria present bind to the photosensitiser-bacteriophage conjugate; and
- (b) irradiating the area with light at a wavelength absorbed by the photosensitiser.

14. (currently amended) A method according to claim 13, wherein the bacteria are staphylococcus, particularly MRSA, EMRSA VRSA, hetero-VRSA or CA-MRSA.

15. (previously presented) A method according to claim 13, wherein the light is laser light or white light.

16. (original) A method according to claim 15, wherein the laser light is from a helium neon gas laser.

17. (previously presented) A method according to claim 15, wherein the laser light has a wavelength of from 200 to 1060 nm.

18. (previously presented) A method according to claim 15, wherein the laser has a power of from 1 to 100 mW and a beam diameter of from 1 to 10 mm.

19. (previously presented) A method according to claim 18, wherein the light dose of laser irradiation is from 5 to 333 Jcm<sup>-2</sup>.

20. (previously presented) A method according to claim 15, wherein the light dose of white light is from 0.01 to 100 J/cm<sup>2</sup>.

21. (previously presented) A method according to claim 15, wherein the duration of irradiation is from one second to 15 minutes.

22. (previously presented) A method according to claim 13, wherein the composition is present in or on the area to be treated at a concentration of from 0.00001 to 1% w/v.

23. (currently amended) ~~Use of a composition according to claim 1,~~ A method for treatment of the human or animal body, comprising administering an effective amount of a composition according to claim 1.

24. (currently amended) ~~Use of a composition according to claim 1, in the manufacture of a medicament~~ A method for treatment of bacterial infection, comprising administering an effective amount of a composition according to claim 1.

25. (currently amended) ~~[[Use]]~~ A method according to claim 24, wherein the bacterial infection is *S. aureus*, ~~particularly MRSA, EMRSA, VRSA, hetero VRSA or CAMRSA.~~

26. (currently amended) ~~[[Use of]]~~ A method of photodynamic therapy (PDT), wherein a bacteriophage is used as a targeting agent ~~in photodynamic therapy (PDT).~~

27. (currently amended) ~~[[Use]]~~ A method according to claim 26, wherein the bacteriophage is a staphylococcal phage.

Claims 28-30 (canceled)

31. (new) A composition according to claim 1, which further comprises calcium chloride.

32. (new) A method according to claim 13, wherein the bacteria are MRSA, EMRSA VRSA, hetero-VRSA or CA-MRSA.

33. (new) A method according to claim 24, wherein the bacterial infection is MRSA, EMRSA VRSA, hetero-VRSA or CA-MRSA.